JPMorgan Strategist Advises Profit-Taking in Pharma, Sees Long-Term Potential in Defence Stocks
Rajiv Batra, JPMorgan's Head of Asia & Co-Head of Global Emerging Markets Equity Strategy, highlights growth and policy as top concerns for global investors in Indian markets. He recommends booking profits in pharma stocks due to US generic investigations and underwhelming earnings. JPMorgan maintains a positive stance on financials but advises monitoring the Jackson Hole Symposium for potential impacts. Batra suggests a structural buy approach for defence stocks, citing increased global budgets, potential foreign partnerships, and India's focus on national security as growth drivers for the next 5-10 years.

*this image is generated using AI for illustrative purposes only.
Rajiv Batra, JPMorgan's Head of Asia & Co-Head of Global Emerging Markets Equity Strategy, has outlined key investment themes for Indian markets, highlighting growth and policy as top concerns among global investors.
Growth and Policy Concerns
Batra noted that investors are seeking double-digit growth in both earnings and nominal GDP before showing renewed interest in India. This indicates a cautious approach from global investors, who are closely monitoring India's economic performance and policy landscape.
Pharma Sector: Time to Book Profits
The strategist recommended taking profits in pharmaceutical stocks, citing two main factors:
- Concerns stemming from US generic investigations under Section 232
- Underwhelming quarterly earnings performance
Batra pointed out that the pharma sector has delivered an impressive 40% outperformance over the past three years. However, it now faces headwinds, including the Revlimid patent expiry, which is expected to reduce earnings contribution from 13% to 1%.
Positive Stance on Financials
JPMorgan maintains a positive outlook on the financial sector. However, Batra advised monitoring the Jackson Hole Symposium for potential impacts on rate cuts, which could affect the sector's performance.
Defence Sector: A Structural Buy
Batra advocated for a structural buy approach to defence stocks, citing several supporting factors:
- Increased global defence budgets
- Potential foreign partnerships
- India's focus on national security
These factors, according to Batra, are likely to drive growth prospects in the defence sector over the next 5-10 years.
Market Implications
Batra's insights suggest a nuanced approach to the Indian market:
- Pharma: Investors might consider reallocating funds from pharmaceutical stocks that have seen significant gains.
- Financials: The sector remains attractive but requires careful monitoring of global monetary policy trends.
- Defence: Long-term investors may find opportunities in defence stocks, given the sector's growth potential.
Investors are advised to conduct their own research and consider their individual risk tolerance before making investment decisions based on these recommendations.